JP Morgan Chase’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

JP Morgan Chase’s Portfolio DCPH Stock Details DCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-30,200	Closed	-$280K	–	7005
2022 Q1	$280K	Sell	30,200 -2,300	-7%	-$19.6K	﹤0.01%	5001
2021 Q4	$318K	Buy	+32,500	New	+$611K	﹤0.01%	5097
2021 Q3	–	Sell	-25,000	Closed	-$915K	–	6898
2021 Q2	$915K	Buy	+25,000	New	+$968K	﹤0.01%	4365
2020 Q4	–	Sell	-40,000	Closed	-$1.98M	–	6010
2020 Q3	$1.98M	Hold	40,000	–	–	﹤0.01%	3246
2020 Q2	$2.39M	Buy	+40,000	New	+$2.14M	﹤0.01%	2990
2020 Q1	–	Sell	-450,000	Closed	-$28M	–	5812
2019 Q4	$28M	Buy	+450,000	New	+$21.4M	0.01%	1324

Other funds holding DCPH

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

JP Morgan Chase's DCPH Position: Q2 2024 in Review

JP Morgan Chase sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2024, closing a stake of 60,453 shares — an estimated $951K sold.

JP Morgan Chase first reported a position in DCPH in Q4 2017 and held it in 26 quarters. The position peaked at $7.52M in Q2 2018. 1 fund tracked by Wall St. Rank holds DCPH as of Q2 2024.

JP Morgan Chase reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
JP Morgan Chase sold 60,453 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $951K.
JP Morgan Chase first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 26 quarters.
JP Morgan Chase's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $7.52M in Q2 2018.
1 fund tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on JP Morgan Chase's 13F filing for Q2 2024, filed 12 Aug 2024.